Clinical Trial Update: Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating temozolomide plus SurVaxM (survivin long peptide vaccine) for progressing metastatic neuroendocrine carcinomas is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Neuroendocrine Tumor
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• SurVaxM (SurVaxM)
• Temodar (Temozolomide)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm | Phase 2 | Status: RECRUITING